Calidi Biotherapeutics CLDI Institutional Ownership

Calidi Biotherapeutics, Inc. (NYSE:CLDI) showed up in the 13F filings of 24 institutional investors as of June 2026.

• Their combined ownership stood at 2.3% of outstanding shares in June 2026, down from 46.7% in March 2026.
• Their total shares held in CLDI increased 51.24% from the prior quarter, while the number of investors in Calidi Biotherapeutics decreased 29.41% year over year.
• Activity in CLDI broke down as 12 buyers, 0 sellers, and 12 unchanged among 24 total holders.
• In total, institutional investors held 32.85K shares in Calidi Biotherapeutics as of June 2026, up by 11.13K shares quarter on quarter, and down 199.01K shares year over year.
• As of June 30, 2026, the biggest holder of Calidi Biotherapeutics is GEODE CAPITAL MANAGEMENT, LLC at 7.16K shares, representing 0.51% of shares outstanding.
• The most significant purchases of CLDI for the quarter ending June 2026 came from GEODE CAPITAL MANAGEMENT, LLC (3.22K), Independent Advisor Alliance (2.81K), Private Advisor Group, LLC (1.88K), JANE STREET GROUP, LLC (1.22K), RFG Advisory, LLC (750).
• Business Quant data shows the 10 biggest positions in Calidi Biotherapeutics as of June 2026 are held by GEODE CAPITAL MANAGEMENT, LLC (7.16K), HighTower Advisors, LLC (5.22K), JANE STREET GROUP, LLC (3.39K), Independent Advisor Alliance (2.81K), RS CRUM INC. (2.7K), Arax Advisory Partners (2.33K), Private Advisor Group, LLC (1.88K), VANGUARD CAPITAL MANAGEMENT LLC (1.59K), Belpointe Asset Management LLC (1.25K), Northern Trust Corp (1.11K).